Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma

By Wersäll Peter   Blomgren Henric   Pisa Pavel   Lax Ingmar   Kälkner Karl-Mikael   Svedman Christer  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 493-497

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma

By Hainsworth John D.   Infante Jeffrey R.   Spigel David R.   Arrowsmith Edward R.   Boccia Ralph V.   Burris Howard A.  

Cancer Investigation, Vol. 29, Iss. 7, 2011-07 ,pp. : 451-455

Informa Healthcare

Access to resources Recommend Favorite

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

By Naito Seiji   Tsukamoto Taiji   Usami Michiyuki   Fujimoto Hiroyuki   Akaza Hideyuki  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

By Koh Y.   Lim H. Y.   Ahn J. H.   Lee J.-L.   Rha S. Y.   Kim Y. J.   Kim T. M.   Lee S.-H.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1026-1031

Oxford University Press

Access to resources Recommend Favorite

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine

By Cohen L.   de Moor C.   Parker P.A.   Amato R.J.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 3, 2002-05 ,pp. : 119-124

Elsevier

Access to resources Recommend Favorite